Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.99 USD
Change Today -0.08 / -1.58%
Volume 221.3K
CORT On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 1:36 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

corcept therapeutics inc (CORT) Snapshot

Open
$5.07
Previous Close
$5.07
Day High
$5.15
Day Low
$4.95
52 Week High
06/22/15 - $7.67
52 Week Low
10/2/14 - $2.59
Market Cap
540.8M
Average Volume 10 Days
389.3K
EPS TTM
$-0.17
Shares Outstanding
108.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORCEPT THERAPEUTICS INC (CORT)

corcept therapeutics inc (CORT) Related Bloomberg News

View More Bloomberg News

corcept therapeutics inc (CORT) Related Businessweek News

No Related Businessweek News Found

corcept therapeutics inc (CORT) Details

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

50 Employees
Last Reported Date: 03/13/15
Founded in 1998

corcept therapeutics inc (CORT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $571.3K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $350.9K
Senior Vice President of Oncology
Total Annual Compensation: $397.4K
Consultant
Total Annual Compensation: $251.8K
Compensation as of Fiscal Year 2014.

corcept therapeutics inc (CORT) Key Developments

Corcept Therapeutics Incorporated Reports Earnings Results for the Second Quarter Ended June 30, 2015; Revised Earnings Guidance for the Full Year 2015

Corcept Therapeutics Incorporated reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company has posted revenue of $11,956,000 against $5,851,000 a year ago. Loss from operations was $1,166,000 against $6,581,000 a year ago. Net loss and comprehensive loss was $1,936,000 or $0.02 basic and diluted per share against $7,552,000 or $0.07 basic and diluted per share a year ago. The company generated net income on a non-GAAP basis of $369,000 in the second quarter of 2015, compared to a non-GAAP net loss of $5.4 million in the second quarter of 2014. For the six months, the company has posted revenue of $22,058,000 against $10,255,000 a year ago. Loss from operations was $5,196,000 against $19,440,000 a year ago. Net loss and comprehensive loss was $6,766,000 or $0.06 basic and diluted per share against $21,481,000 or $0.21 basic and diluted per share a year ago. The company has revised its 2015 revenue guidance from $47 million­ $53 million to $49 million­ $53 million.

Corcept Therapeutics Incorporated to Report Q2, 2015 Results on Aug 05, 2015

Corcept Therapeutics Incorporated announced that they will report Q2, 2015 results on Aug 05, 2015

Corcept Therapeutics Incorporated, Q2 2015 Earnings Call, Aug 05, 2015

Corcept Therapeutics Incorporated, Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORT:US $4.99 USD -0.08

CORT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.94.20 CHF -0.15
View Industry Companies
 

Industry Analysis

CORT

Industry Average

Valuation CORT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.1x
Price/Book 47.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORCEPT THERAPEUTICS INC, please visit www.corcept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.